All Articles

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

The Ontario Science Centre's event with astronaut Jeremy Hansen is more than a celebration; it's a strategic play for relevance and a national talent drive.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

A Toronto meeting signals a new era for Canada-Grenada ties. It's a calculated move into geothermal energy, regional security, and high-value trade.

The federal government hails its new AI strategy as 'pro-worker,' but a major public service union warns it lacks crucial safeguards, risking jobs and services.

Ottawa unveils a multi-billion dollar plan to transform Canada from an AI research hub into an economic leader, focusing on adoption, sovereignty, and ethics.

Ottawa's new "AI for All" plan promises to revolutionize healthcare, but can its 'ironclad protections' keep pace with the technology it's unleashing?

As whistleblower law gains formal recognition, a top-tier ranking for Pugsley Wood LLP signals a new era of corporate accountability and strategic risk.

Wilson Elser’s 2026 Chambers rankings reveal more than legal wins; they map a strategy of mastering niche markets from cannabis law to NTSB disasters.

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

With record profits and a booming backlog, M-tron Industries is pitching its critical role in national security to top investors. Here's why they're listening.

A new alliance between General Fluidics and Invetech seeks to move lab testing from centralized facilities to the clinic, promising faster, more accessible care.

As AI and crypto converge, a new project bets its future not on speculation, but on tangible utility and verifiable security. We deconstruct the model.

A new open standard called Aliro, backed by industry giants, is set to revolutionize access control, promising a future free from proprietary walled gardens.

A small biotech just unveiled data for an oral weight-loss pill that appears twice as effective as a key competitor in early tests, shaking up the market.

A breakthrough biomarker, DNlite™, analyzes landmark trial data, offering a new way to identify high-risk diabetes patients missed by current standards.

PrivacyHawk's new RoboHawk feature promises immediate silence from spam calls while its core service scrubs your data. But is this all-in-one fix the future?

The insurance giant's new 'aa' rated surplus notes aren't just debt; they are a strategic move to fortify its capital fortress and fuel future growth.

With Brian Ewart's appointment as General Counsel, the nonprofit signals a new era of disciplined growth, leveraging top legal talent to navigate complex federal contracts.